851883-08-4

Basic information

• Product Name: 3,4-DIAMINOPHENYLBORONIC ACID, PINACOL ESTER
• Synonyms: 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1,2-diamine;4-(tetraMethyl-1,3,2-dioxaborolan-2-yl)benzene-1,2-diaMine;4-(4,4,5,5-TetraMethyl-1,3,2-dioxaborolan-2-yl)-1,2-benzenediaMine;3,4-DIAMINOPHENYLBORONIC ACID, PINACOL ESTER
• CAS NO: 851883-08-4
• Molecular Formula: C₁₂H₁₉BN₂O₂
• Molecular Weight: 234.1
• Mol File: 851883-08-4.mol
• Article Data: 23

Chemical Properties

• Appearance: off-white solid
• Density: 1.10
• CAS DataBase Reference: 3,4-DIAMINOPHENYLBORONIC ACID, PINACOL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIAMINOPHENYLBORONIC ACID, PINACOL ESTER(851883-08-4)
• EPA Substance Registry System: 3,4-DIAMINOPHENYLBORONIC ACID, PINACOL ESTER(851883-08-4)

Safety Data

• Hazardous Substances Data: 851883-08-4(Hazardous Substances Data)

Usage

General Description

3,4-Diaminophenylboronic acid pinacol ester is a chemical compound that is used in organic synthesis and drug development. It is a boronic acid derivative with two amino groups and a pinacol ester functional group. 3,4-DIAMINOPHENYLBORONIC ACID, PINACOL ESTER is often used as a reagent in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is known for its ability to form stable complexes with diols, making it a valuable tool in the development of new drugs and other bioactive molecules. Additionally, 3,4-diaminophenylboronic acid pinacol ester has been studied for its potential to inhibit the growth of cancer cells, making it a promising candidate for further research in the field of oncology.

InChI:InChI=1S/C12H19BN2O2/c1-11(2)12(3,4)17-13(16-11)8-5-6-9(14)10(15)7-8/h5-7H,14-15H2,1-4H3

Upstream product

• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 73183-34-3 bis(pinacol)diborane 
• 833486-94-5 4-amino-3-nitrophenylboronic acid pinacol ester 
• 849236-22-2 2-nitro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 
• 875-51-4 4-Bromo-2-nitroaniline 
• 1075719-78-6 2-(3,4-dibromophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Downstream Products

• 851883-10-8 4-[2,7-di-tert-butyl-5-(3,4-diamino-phenyl)-9,9-dimethyl-9H-xanthen-4-yl]-benzoic acid methyl ester 
• 916843-29-3 4-[2,7-di-tert-butyl-5-(3,4-diamino-phenyl)-9,9-dimethyl-9H-xanthen-4-yl]-benzoic acid 
• 937047-96-6 C₂₀H₂₃BN₂O₂ 
• 710348-69-9 5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one 
• 937047-96-6 2-benzyl-1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole 
• 1149613-77-3 2-(2-chlorobenzyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1Hbenzo[d]imidazole 
• 943975-06-2 2-(2-methoxybenzyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole 
• 1257250-81-9 N-phenyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazol-2-amine 
• 1318899-03-4 (R)-2-phenyl-1-((S)-2-(5-(6-(2-((2S,3aS,7aS)-1-((R)-2-phenyl-2-(pyrrolidin-1-yl)acetyl)octahydro-1H-indol-2-yl)-1H-benzo[d]imidazol-5-yl)naphthalen-2-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-2-(pyrrolidin-1-yl)ethanone 
• 1318898-96-2 (S)-tert-butyl 2-(5-(6-(3,4-diaminophenyl)naphthalen-2-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1318898-49-5 1,1-dimethylethyl (2S,4S)-2-{4-[6-(3,4-diaminophenyl)-2-naphthalenyl]-1H-imidazol-2-yl}-4-methyl-1-pyrrolidinecarboxylate 
• 1318898-80-4 methyl {(1S)-1-[((2S,4S)-2-{4-[6-(3,4-diaminophenyl)-2-naphthalenyl]-1H-imidazol-2-yl}-4-methyl-1-pyrrolidinyl)carbonyl]-2-methylpropyl}carbamate 
• 1296797-03-9 bis(1,1-dimethylethyl)(3,4-diamino-1,1':4',1-terphenyl-3,4-diyl)biscarbamate 
• 1296797-04-0 methyl [(1S)-1-({(8S)-8-[5-(3',4'-diamino-4-biphenylyl)-1H-benzimidazol-2-yl]-1,4-dioxa-7-azaspiro[4.4]non-7-yl}carbonyl)-2-methylpropyl]carbamate 

Relevant articles and documents

Immunomodulator

The invention discloses an immunomodulator, and particularly relates to compounds for inhibiting IL-17A and application of the compounds serving as the immunomodulator in preparation of drugs. The invention discloses an application of a compound shown as a formula I or a stereoisomer thereof in preparing medicines for inhibiting IL-17A, and provides a new choice for clinically screening and/or preparing medicines for treating diseases related to IL-17A activity.

Discovery of BAY-985, a Highly Selective TBK1/IKK? Inhibitor

The serine/threonine kinase TBK1 (TANK-binding kinase 1) and its homologue IKK? are noncanonical members of the inhibitor of the nuclear factor κB (IκB) kinase family. These kinases play important roles in multiple cellular pathways and, in particular, in inflammation. Herein, we describe our investigations on a family of benzimidazoles and the identification of the potent and highly selective TBK1/IKK? inhibitor BAY-985. BAY-985 inhibits the cellular phosphorylation of interferon regulatory factor 3 and displays antiproliferative efficacy in the melanoma cell line SK-MEL-2 but showed only weak antitumor activity in the SK-MEL-2 human melanoma xenograft model.

HETEROARYLBENZIMIDAZOLE COMPOUNDS

The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.